Intersect ENT Inc (NASDAQ:XENT) traded down 8.9% during mid-day trading on Monday . The company traded as low as $23.09 and last traded at $24.38, 1,163,589 shares traded hands during trading. An increase of 49% from the average session volume of 780,586 shares. The stock had previously closed at $26.76.
A number of analysts have recently issued reports on the stock. Piper Jaffray Companies set a $21.00 price target on shares of Intersect ENT and gave the company a “hold” rating in a report on Friday, November 1st. JPMorgan Chase & Co. raised their price target on shares of Intersect ENT from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Finally, BidaskClub downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $27.25.
The company has a market cap of $843.34 million, a PE ratio of -19.05 and a beta of 0.91. The business’s fifty day moving average is $25.87 and its 200-day moving average is $20.87.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Monday, February 24th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.10. The company had revenue of $31.70 million for the quarter, compared to the consensus estimate of $31.60 million. Intersect ENT had a negative net margin of 36.37% and a negative return on equity of 34.19%. The firm’s revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) earnings per share. As a group, equities analysts expect that Intersect ENT Inc will post -1.48 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG boosted its holdings in shares of Intersect ENT by 7.0% in the fourth quarter. UBS Group AG now owns 1,487,366 shares of the medical equipment provider’s stock worth $37,035,000 after buying an additional 97,386 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Intersect ENT by 39.6% in the fourth quarter. Jennison Associates LLC now owns 820,608 shares of the medical equipment provider’s stock worth $20,433,000 after buying an additional 232,765 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Intersect ENT by 49.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 812,720 shares of the medical equipment provider’s stock worth $20,237,000 after buying an additional 269,666 shares during the last quarter. State Street Corp boosted its holdings in shares of Intersect ENT by 5.1% in the third quarter. State Street Corp now owns 726,772 shares of the medical equipment provider’s stock worth $12,362,000 after buying an additional 35,130 shares during the last quarter. Finally, Man Group plc boosted its holdings in shares of Intersect ENT by 4.4% in the third quarter. Man Group plc now owns 659,034 shares of the medical equipment provider’s stock worth $11,210,000 after buying an additional 27,762 shares during the last quarter. 99.14% of the stock is currently owned by institutional investors.
About Intersect ENT (NASDAQ:XENT)
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
